« Previous AbstractAn Idiographic Investigation of Diabetic Alert Dogs' Ability to Learn From a Small Sample of Breath Samples From People With Type 1 Diabetes    Next Abstract"Exploring the volatile metabolites of three Chorisia species: Comparative headspace GC-MS, multivariate chemometrics, chemotaxonomic significance, and anti-SARS-CoV-2 potential" »

Pediatr Blood Cancer

Title:		Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia
Author(s):		Reeves SL; Dombkowski KJ; Peng HK; Phan H; Kolenic G; Creary SE; Madden B; Lisabeth LD;
Address:		"Department of Pediatrics, Susan B Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, MI, United States. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States. College of Pharmacy, University of Michigan, Ann Arbor, MI, United States. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, United States. Center for Child Health Equity and Outcomes Research, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, United States"
Journal Title:		Pediatr Blood Cancer
Year:		2023
Volume:		20230412
Issue:		7
Page Number:		e30332 -
DOI:		10.1002/pbc.30332
ISSN/ISBN:		1545-5017 (Electronic) 1545-5009 (Linking)
Abstract:		"OBJECTIVE: Hydroxyurea lowers the incidence of vaso-occlusive pain crises (VOC) and acute chest syndrome (ACS) among children with sickle cell anemia (SCA). Our objective was to assess the relationship between levels of adherence to hydroxyurea and clinical outcomes among children and adolescents with SCA. METHODS: This retrospective cohort study included Medicaid data (2005-2012) from Florida, Illinois, Louisiana, Michigan, South Carolina, and Texas. The study population consisted of children 1-17 years old with SCA enrolled in Medicaid for 3 years. Among children that initiated hydroxyurea, the medication possession ratio (MPR) was calculated as the proportion of days covered by hydroxyurea. Six months after initiation of hydroxyurea, clinical outcomes were assessed through the end of the study period: numbers of VOC-related inpatient admissions and emergency department visits, and encounters for ACS. Multivariable Poisson models were used to predict outcomes by MPR quartile adjusting for previous healthcare utilization, state, and age. RESULTS: Hydroxyurea was initiated by 515 children. The median MPR was 0.53 (interquartile range = 0.3-0.8). The annual median number of visits was 0.0 for ACS, 1.3 for VOC-related emergency department, and 1.4 for VOC-related inpatient admissions. For each outcome, the highest quartile of MPR had the lowest predicted count; this difference was significant for ACS visits when compared with the lowest quartile of MPR. CONCLUSION: This study demonstrated a high level of adherence (>75%) was essential to achieve a lower incidence of common negative clinical outcomes. Further, moderate and severe hydroxyurea nonadherence may be more common than previously appreciated among children, emphasizing the importance of developing and testing innovative strategies to increase adherence"
Keywords:		"Adolescent Humans Child Infant Child, Preschool Hydroxyurea/therapeutic use Retrospective Studies *Volatile Organic Compounds/therapeutic use *Anemia, Sickle Cell/drug therapy *Acute Chest Syndrome/drug therapy Antisickling Agents/therapeutic use acute ca;"
Notes:		"MedlineReeves, Sarah L Dombkowski, Kevin J Peng, Hannah K Phan, Hanna Kolenic, Giselle Creary, Susan E Madden, Brian Lisabeth, Lynda D eng K01 HL132057/HL/NHLBI NIH HHS/ Research Support, N.I.H., Extramural 2023/04/14 Pediatr Blood Cancer. 2023 Jul; 70(7):e30332. doi: 10.1002/pbc.30332. Epub 2023 Apr 12"